Product
Supplier
Encyclopedia
Inquiry
Home > Biochemical Engineering > Polypeptide > Erdafitinib for Sale > Erdafitinib High Quality 99% powder 1346242-81-6
Erdafitinib  High Quality 99% powder 1346242-81-6 buy - large image1
Erdafitinib  High Quality 99% powder 1346242-81-6 buy - image1
Erdafitinib  High Quality 99% powder 1346242-81-6 buy - image2
Erdafitinib  High Quality 99% powder 1346242-81-6 buy - image3
Erdafitinib  High Quality 99% powder 1346242-81-6 buy - image4
Erdafitinib  High Quality 99% powder 1346242-81-6 buy - image5
Erdafitinib  High Quality 99% powder 1346242-81-6 buy - image6

Erdafitinib High Quality 99% powder 1346242-81-6

798 Inquiries

Unit Price:

$80/G FOB

Get Latest Price
CAS No.:

1346242-81-6

Grade:

Pharmaceutical Grade

Content:

99%

Port:

hk

Brand:

a1

Packaging:

Double plastic bags plus aluminum foil bag

Sample Available:

Yes

Price valid (until):

2026-12-05

Company Type:
Trader
Location:
China
Average Lead Time:
365 days
Qualification:
Main Products:

Peptide,Skincare

  • Product Details

  • Seller Information

  • Inquiry History

  • Description

    WA: +852 70911333  Email: ogunjitakusaz@outlook.com

     

    Our Core Peptide Offerings and Premium Freeze-Dried Powder

    At our company, we take pride in offering a diverse portfolio of peptide-based products designed to meet the varied needs of our customers. Our range includes innovative solutions for beauty enhancement, weight management, tanning, and more, all developed through the latest scientific research. We are committed to translating cutting-edge discoveries into highly effective, safe, and reliable peptide products, providing exceptional value to our clients.

    Beauty Peptides

    Our beauty peptides are among our flagship offerings, renowned for their safety and effectiveness. They work by stimulating collagen production, enhancing skin elasticity, and reducing fine lines and wrinkles. These peptides promote a smoother, more delicate complexion and possess antioxidant and anti-inflammatory properties, helping to defend against environmental damage and delay the aging process. Their efficient and safe characteristics have made them a favorite among consumers seeking youthful, radiant skin.

    Weight Loss Peptides

    Our weight management peptides are designed to support healthy and sustainable weight loss. They function by boosting metabolism, suppressing appetite, and facilitating fat breakdown. Importantly, these peptides help reduce body fat while preserving muscle mass, thereby preventing issues like skin sagging during weight loss. They are an ideal choice for individuals pursuing a healthy lifestyle and improved physical appearance.

    Tanning Peptides

    Our tanning peptides stimulate melanin production, enabling users to achieve a natural, healthy tan. By activating skin melanocytes, these peptides gradually darken the skin while also providing some degree of sun protection, reducing the risk of UV damage. They are simple to apply, effective, and serve as an excellent alternative for those seeking a safe, natural-looking tan without excessive sun exposure.

    Unparalleled Freeze-Dried Powder Technology

    In addition to our peptide products, we offer a premium freeze-dried powder that stands out for its comprehensive advantages in quality, performance, and value. We firmly believe that this lyophilized powder is a superior solution for various applications, thanks to its innovative preservation method.

    Key Benefits:

     

    Ultra-Low Temperature Preservation: The powder is stored at -196 ° C, causing the active components to enter a dormant state, which preserves their integrity and potency over time.

     

    This freeze-dried powder is ideal for customers seeking high-quality, stable, and easy-to-use peptide . We offer a wide selection of peptide products, all of which are crafted to meet strict quality standards. Our competitive pricing ensures that clients receive the best value for their investment.

    Customer Satisfaction and Support

    Our commitment to excellence is reflected in the positive feedback from our clients, many of whom have expressed satisfaction with the quality, efficacy, and reliability of our peptides and freeze-dried powders. We are always available to answer questions, provide guidance, and help our clients leverage our products to achieve their business goals.

    If you are interested in learning more about our products or exploring how they can add value to your operations, please do not hesitate to contact us. We look forward to partnering with you to support your success and help you stay ahead in this rapidly evolving industry.

    Company Profile

     

    Overview:  

    We specialize in high-purity peptide products, with each batch produced on dedicated production lines to ensure purity levels exceeding 99%. Our commitment to quality and innovation makes us a trusted partner in the global research, pharmaceutical, and healthcare industries.

     

    Quality Assurance:  

    All our products undergo rigorous testing and quality control under strict management systems. We provide comprehensive documentation — including Certificates of Analysis — to verify purity, potency, and compliance with international standards, ensuring reliability and transparency for our clients.

     

    Global Reach and Service:  

    With extensive experience and a wide-reaching logistics network, we offer door-to-door delivery and customs clearance assistance for clients worldwide, including the USA, Canada, Australia, Europe, and many other regions. Our dedicated customer service team is committed to providing prompt, responsive support.

     

    Core Values:  

    - Integrity: We operate honestly and transparently, earning the trust of customers, partners, and society.  

    - Quality First: We prioritize safety, effectiveness, and exceeding customer expectations in every product we deliver.  

    - Collaborative Growth: We foster open cooperation with research institutions, universities, and industry partners to create shared value and mutual success.  

    - Innovation and Learning: We continuously explore new scientific frontiers, improve our technologies, and encourage ongoing employee development to stay at the forefront of biotechnology.

     

    Mission:  

    To advance scientific research and healthcare innovation worldwide by providing premium-quality peptides, supporting the development of healthier lives and a brighter future.

     

    FAQ

    1、 What types of peptides do you manufacture?

    We specialize in a variety of high-purity peptides, including custom peptides, research-grade peptides, cosmetic peptides, and peptide lyophilized powders and raw materials for pharmaceutical applications.

    2 、 What is the typical purity of your peptides?

    Our peptides are typically ≥ 99% pure, and we provide detailed COA (Certificate of Analysis).

    3 、 What if I need technical support after purchasing?

    Our technical and sales support team are always here to answer any questions you may have before or after your purchase. Please contact us via WhatsApp or email or form, we will usually respond within 12 hours.

    4 、 Do you ship internationally?

    Yes, we ship to over 35 countries and regions worldwide and provide full order tracking. If you have special shipping requirements, please let us know in advance.

    5 、 What payment methods do you accept?

    We support multiple secure payment methods, including: BTC/ETH/USDT/USDC/Alipay/etc.

    6 、 How long does it take to process and ship my order?

    Standard peptides: We will send out the goods within three days after receiving your payment, and the estimated delivery time is 5~15  days.

     

     

    Item

    Specifications

    MOQ

    1box

    Package

    Box

    Port

    HK

     

    ECHEMI Editorial Reference
    Erdafitinib (JNJ-42756493) is a potent and orally available FGFR family inhibitor; inhibits FGFR1/2/3/4 with IC50s of 1.2, 2.5, 3.0 and 5.7 nM, respectively.
    In early April of 2019, the US FDA approved Janssen Pharmaceutical Companies' brand name Balversa (erdafitinib) as the first-ever fibroblast growth factor receptor (FGFR) kinase inhibitor indicated for patients with locally advanced or metastatic urothelial carcinoma, with susceptible FGFR3 or FGFR2 genetic alterations, that has progressed during or following platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy. At the same time, the FDA also approved the therascreen FGFR RGQ RT-PCR Kit (Qiagen) for utilization as a companion diagnostic with erdafitinib for selecting patients for the indicated therapy. Erdafitinib's innovation lies in the fact that it is the first personalized treatment targeting susceptible FGFR genetic alterations for patients with metastatic bladder cancer, which demonstrates the design of erdafitinib in developing more personalized and precision medicines with the capacity to target cancer treatment to a patient's specific genetic mutation. Considering urothelial cancer is statistically the fourth most common kind of cancer in the world, the introduction of erdafitinib offers a welcome new option in the ever-expanding therapeutic tool kit to treat such prevalent medical conditions. Nevertheless, although erdafitinib was granted Breakthrough Therapy designation and Accelerated Approval from the FDA so as to allow the agency to focus on and expedite the approval process for a medication indicated for a serious condition that fills an unmet medical need using clinical trial data that is believed to predict a genuine clinical benefit for patients with the given condition, such designations mean further ongoing clinical trials are necessary to confirm the clinical benefit of erdafitinib going forward.|Erdafitinib is an oral small molecule inhibitor of fibroblast growth factor receptors (FGFR) 1 to 4 that is used in the therapy of locally advanced, unresectable or metastatic urothelial carcinoma. Erdafitinib has been associated with a high rate of serum enzyme elevations during therapy, but has not been linked to cases of clinically apparent acute liver injury.|Erdafitinib is an orally bioavailable, pan fibroblast growth factor receptor (FGFR) inhibitor with potential antineoplastic activity. Upon oral administration, erdafitinib binds to and inhibits FGFR, which may result in the inhibition of FGFR-related signal transduction pathways and thus the inhibition of tumor cell proliferation and tumor cell death in FGFR-overexpressing tumor cells. FGFR, upregulated in many tumor cell types, is a receptor tyrosine kinase essential to tumor cell proliferation, differentiation and survival.

    Basic Info
    Product Name:

    Erdafitinib

    Other Name:

    1,2-Ethanediamine,N1-(3,5-dimethoxyphenyl)-N2-(1-methylethyl)-N1-[3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl]-;N1-(3,5-Dimethoxyphenyl)-N2-(1-methylethyl)-N1-[3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl]-1,2-ethanediamine;Erdafitinib;JNJ 42756493;Balversa;1620332-47-9

    CAS No.:

    1346242-81-6

    Molecular Formula:

    C25H30N6O2

    InChIKeys:

    InChIKey=OLAHOMJCDNXHFI-UHFFFAOYSA-N

    Molecular Weight:

    446.54

    Exact Mass:

    446.54

    UNII:

    890E37NHMV

    NCI Thesaurus Code:

    C103273

    ATC Code:

    L - Antineoplastic and immunomodulating agents

    Categories:

    Polypeptide

    Characteristics
    PSA:

    77.3

    XLogP3:

    3.2

    Density:

    1.2±0.1 g/cm3

    Flash Point:

    354.4±31.5 °C

    Refractive Index:

    1.618

    Water Solubility:

    <1 mg/mL

    Research
    Class:

    Pan-FGFR tyrosine kinase inhibitor (FGFR1-4); antineoplastic (ATC L01EN01)

    Status:

    Approved (FDA accelerated approval 2019-04-12; converted to regular approval 2024-01-19; EMA approval 2024-08)

    Mechanism:

    Erdafitinib is an orally bioavailable, functionally selective small-molecule inhibitor of fibroblast growth factor receptors 1-4 (FGFR1-4). It inhibits FGFR tyrosine kinase activity (IC50 1.2-5.7 nM), blocking downstream RAS-MAPK/ERK and PI3K-AKT signaling that drives proliferation and survival of tumor cells harboring activating FGFR alterations (mutations, amplifications, or fusions). Rapid lysosomal uptake contributes to prolonged inhibition of FGFR signaling.

    EC50 (Fgfr1 Ic50):

    1.2 nM

    EC50 (Fgfr3 Ic50):

    3.0 nM

    EC50 (Fgfr2 Ic50):

    2.5 nM

    EC50 (Fgfr4 Ic50):

    5.7 nM

    EC50 (Vegfr2 Ic50):

    36.8 nM (approximately 30-fold selectivity vs FGFR1)

    Source:

    Perera TPS, et al. Mol Cancer Ther. 2017;16(6):1010-1020.DOI

    Clinical Development:

    NCT02365597 ; NCT03390504

    FDA:

    Balversa (approved 2019-04-12)

    References
    ChEMBL:

    CHEMBL3545376

    DrugBank:

    DB12147

    KEGG DRUG:

    D10927

    PubChem:

    PubChem

    Disclaimer:

    Erdafitinib (Balversa) is a prescription medicine approved by the US FDA and the EMA for specific oncology indications. ECHEMI lists this product for industrial sourcing and supply-chain reference only. Product information on ECHEMI is provided for sourcing and specification reference. It is not medical advice, a clinical recommendation, or a substitute for approved therapy. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.

    Hazard Identification

    Classification of the substance or mixture

    Acute toxicity - Category 4, Oral

    Skin sensitization, Sub-category 1B

    Serious eye damage, Category 1

    Reproductive toxicity, Category 2

    Specific target organ toxicity – repeated exposure, Category 1

    GHS label elements, including precautionary statements

    Pictogram(s)
    Signal word

    Danger

    Hazard statement(s)

    H302 Harmful if swallowed

    H317 May cause an allergic skin reaction

    H318 Causes serious eye damage

    H361 Suspected of damaging fertility or the unborn child

    H372 Causes damage to organs through prolonged or repeated exposure

    Precautionary statement(s)
    Prevention

    P264 Wash ... thoroughly after handling.

    P270 Do not eat, drink or smoke when using this product.

    P261 Avoid breathing dust/fume/gas/mist/vapours/spray.

    P272 Contaminated work clothing should not be allowed out of the workplace.

    P280 Wear protective gloves/protective clothing/eye protection/face protection/hearing protection/...

    P203 Obtain, read and follow all safety instructions before use.

    P260 Do not breathe dust/fume/gas/mist/vapours/spray.

    Response

    P301+P317 IF SWALLOWED: Get medical help.

    P330 Rinse mouth.

    P302+P352 IF ON SKIN: Wash with plenty of water/...

    P333+P317 If skin irritation or rash occurs: Get medical help.

    P321 Specific treatment (see ... on this label).

    P362+P364 Take off contaminated clothing and wash it before reuse.

    P305+P354+P338 IF IN EYES: Immediately rinse with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.

    P317 Get medical help.

    P318 IF exposed or concerned, get medical advice.

    P319 Get medical help if you feel unwell.

    Storage

    P405 Store locked up.

    Disposal

    P501 Dispose of contents/container to an appropriate treatment and disposal facility in accordance with applicable laws and regulations, and product characteristics at time of disposal.

    Other hazards which do not result in classification

    no data available

    Handling and Storage

    Precautions for safe handling

    Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.

    Conditions for safe storage, including any incompatibilities

    Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.

  • Seller Information
    Business Type:

    Trader

    Main Products:

    Peptide,Skincare

    Location:

    Room 801, T095, No. 169 Haibin Road, Nansha Street, Nansha District, Guangzhou City

    Average lead Time:

    365 days

    Total Annual Revenue:

    $5 million-$10 million

    Total Employees:

    11-50

    Year of Establishment:

    2026

  • Inquiry History
    798 Inquiries
    Country Product Purchase Quantity Date Posted
    Denmark

    Erdafitinib

    1 G Nov 9, 2026
    United Kingdom

    Erdafitinib

    1 G Nov 9, 2026
    Ireland

    Erdafitinib

    1 KG Nov 9, 2026
    United Kingdom

    Erdafitinib

    1 G Nov 9, 2026
    United States

    Erdafitinib

    1 G Nov 9, 2026
    Belgium

    Erdafitinib

    1 G Nov 9, 2026
    United States

    Erdafitinib

    1 G Nov 8, 2026
    Brazil

    Erdafitinib

    3.5 G Nov 8, 2026
    Germany

    Erdafitinib

    1 G Nov 8, 2026
    Israel

    Erdafitinib

    1 G Nov 8, 2026
    Turkey

    Erdafitinib

    1 G Nov 8, 2026
    Lithuania

    Erdafitinib

    1 G Nov 8, 2026
    Germany

    Erdafitinib

    2 G Nov 8, 2026
    United States

    Erdafitinib

    1 G Nov 8, 2026
    Brazil

    Erdafitinib

    2 MG Nov 8, 2026
    United States

    Erdafitinib

    500 MG Nov 8, 2026
    Romania

    Erdafitinib

    20 G Nov 8, 2026
    United States

    Erdafitinib

    1 G Nov 8, 2026
    United States

    Erdafitinib

    1 G Nov 8, 2026
    India

    Erdafitinib

    1 G Nov 7, 2026
    Post an enquiry for this product
pic ×

Scan the QR Code to Share

All products displayed on this website are only for non-medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.

According to relevant laws and regulations and the regulations of this website, units or individuals who purchase hazardous materials should obtain valid qualifications and qualification conditions.

The information shown above is provided by the enterprise itself, and the authenticity, accuracy and legitimacy of the content are the responsibility of the publishing company. ECHEMI does not bear any guarantee responsibility for this. Please be aware that risks in internet transactions objectively exist.

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.